Pulmonary Vein StenosisNCT03456193
Allogeneic Left Atrial and Pulmonary Vein Transplant for Pulmonary Vein Stenosis
A study testing LA transplant in people with Pulmonary Vein Stenosis, run by Boston Children's Hospital at 1 site in United States.
Trial summary
This is a prospective, single center, safety and feasibility trial to evaluate the transplantation of the left atrium and pulmonary veins in patients with pulmonary vein stenosis. Consented patients will be listed for transplantation. Read more about this study
- Who is it for?
- Ages Up to 17 years
- Conditions the study is for
- Pulmonary Vein Stenosis
- What is being tested?
- LA transplant
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 0 participants
- Where
- 1 siteUnited States
- Study dates
- Sep 2022to Sep 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Up to 17 years
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- Pulmonary vein stenosis involving at least one but up to all of the main pulmonary veins following initial treatment, including but not limited to balloon dilation, stenting, surgical repair or chemotherapy
- Focal pulmonary stenosis limited to the main pulmonary veins or their first or second order branches.
Who cannot join
- Diffuse pulmonary vein stenosis involving long segments of one or more pulmonary veins including diffuse stenosis into the second order pulmonary vein branches or beyond
- Significant underlying lung disease
- Irreversible pulmonary artery hypertension exceeding indexed 10 Woods units (WU)
- Irreversible multisystem organ failure; or additive effects of multiple systems affected making transplant survival unlikely
- Progressive systemic disease with early mortality (genetic/metabolic, idiopathic, syndromic)
- Morbid obesity (BMI>30)
Show all 18Show fewer
- Diabetes mellitus with evidence of end-organ damage
- Severe chromosomal, neurologic or syndromic abnormalities
- Active infection
- HIV or chronic hepatitis B or C infection
- Severe left ventricular dysfunction
- Malignancy within 5 years prior to transplant
- Severe renal or liver failure
- Inadequate social support for post-transplant management
- Recent history of illicit drug, tobacco or alcohol abuse despite trials/assistance to stop behavior
- Episode of acute rejection within the previous 6 months
- Post-transplant lymphoproliferative disease that has been within two years
- Evidence of large stroke with high risk for hemorrhagic conversion
Trial locations and contacts
1 site in 1 country.
United States1 site
Boston Children's Hospital
Boston, Massachusetts, 02115
About this study
This is a prospective, single center, safety and feasibility trial to evaluate the transplantation of the left atrium and pulmonary veins in patients with pulmonary vein stenosis. Consented patients will be listed for transplantation. Once a suitable donor has been identified, the left atrium, pulmonary veins and complete lung block will be harvested from the donor and transported to Boston Children's Hospital as is the procedure for routine lung transplantation patients. The left atrium and pulmonary veins will be transplanted into the recipient. The recipient will receive the normal immunosuppression protocol used for heart transplantation.
This pilot study will include 5 patients.
Read the detailed description
Techniques for harvest of the posterior left atrium and pulmonary veins from a suitable organ donor have been well established as this is currently accomplished during every harvest of lungs for lung transplantation. The difference in this therapy is that the lung parenchyma will not be utilized. However, the harvest from the donor will be exactly the same with the full lung block typically harvested for lung transplant removed and transported back to the site of implantation. The exact extent of pulmonary vein utilization from the lung block will be determined at the time of implantation based on the exact anatomy and location of the pulmonary vein disease of the recipient.
As this represents a new transplantation approach, this program has been discussed with the United Network for Organ Sharing (UNOS) and the New England Organ Bank (NEOB). UNOS identified this as a new area of transplantation related to but separate from heart or lung transplantations. Eventually if this progresses to a national phase, it will require creation of a new patient waiting list and all the policies that accompany a new area of transplantation. Although there is enthusiasm at UNOS for this approach, they recommended that it be pursued as a regional research program as an initial step. The NEOB also has voiced support for this program in a meeting with them including their medical director. They are interested in supporting this program as a Region 1 research program and will perform a full evaluation for approval once local IRB approval has been granted. The Children's team will work closely with NEOB to create a list of potential patients and identify suitable donors.
Utilizing standardized harvesting techniques will minimize any changes to the current harvest approach and definition of tissue allocation during the harvest procedure. As the lung parenchyma is unnecessary, it is expected that suitable donors for left atrial transplant would come from two sources:
- The first source is brain dead donors in whom the lungs are not allocated for transplantation based on rejection of the lungs for quality or no matching donors.
- The second source is donors after cardiac death (DCD) which are utilized in the adult population for kidney, liver and lung transplantation. DCD organs are not currently utilized pediatric lung transplantation. However, as the viability of these tissues, including the entire lung block is well established, these represent a potential donor pool for left atrial transplant patients.
Certainly experience with preservation of the kidney grafts for hours or days with integrated perfusion systems has demonstrated the successful implantation of vascularized tissues appropriately preserved can be extended beyond the traditional four hour window targeted for lung transplantation. Kidney transplants are commonly done within 24 hours without evidence of impact on the vascular patency these grafts. In addition, only vascular tissue is being transplanted that has no effect on gas exchange or contractility. Accordingly it is expected that the goal implantation time for left atrial transplants after harvest will not need to be within the four to six hour window used for lung transplant but can be safely extended to 24 hours. This window extends the donor pool for left atrial transplants to the entire country.
Excision of recipient left atrium and stenotic pulmonary veins and implantation of left atrial graft The set up for the operation will be identical to all major cardiopulmonary bypass cardiac cases. The surgical approach for the recipient will likely be a clamshell incision that crosses the sternum in the fourth interspace. This is the same incision used for lung transplant. The patient will be cannulated for cardiopulmonary bypass in the distal aorta, SVC and low in the IVC. Cardiopulmonary bypass will be initiated and the patient will be cooled to 18°C. Prior to arresting the heart, the donor left atrium and pulmonary veins will be inspected in the lung block. The pulmonary veins from the donor will be mobilized and prepared for resection from the lung block.
The cross clamp will be applied and the heart arrested. The pulmonary veins of the recipient will be mobilized and transected beyond the level stenoses. The left atrium and pulmonary vein graft then be brought to the field and positioned in the orthotopic position.
The anastomosis of the pulmonary veins will be completed with a generous diameter of the anastomotic area to minimize any risk of late anastomotic narrowing even in the smallest of pulmonary vein segments. The donor left atrium will be anastomosed to the posterior left atrial cuff of the heart. Only the affected pulmonary veins with stenosis will be transplanted. This may be one or up to all 4 main pulmonary veins. If an individual pulmonary vein or side of pulmonary veins are unaffected, they will not have any manipulation or intervention on them. A formal atrial fenestration will be created. Post-bypass evaluation with transesophageal echocardiogram will assess pulmonary vein velocities and flow. The chest will be closed and patient transferred intubated to the ICU.
In the initial clinical experience with these transplants, a traditional immunosuppression protocol for heart transplants will be followed. Over time new protocols will be developed and tested which focused on minimizing the long-term immunosuppression regimens.
- Conditions
- Pulmonary Vein Stenosis
- Being tested
- LA transplant
- Medical subject headings
- Stenosis, Pulmonary Vein
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
LA transplantProcedure or surgery
The proposed study treatment will include three central components:
- Harvest of the left atrium and pulmonary veins from a suitable donor
- Excision of the left atrium and portions of stenotic pulmonary veins from the patient with pulmonary vein stenosis
- Implantation of the donor posterior left atrium and portions of pulmonary veins into the patient.
| Study group | Role | What they receive |
|---|---|---|
| LA transplantation | Experimental | The left atrium and pulmonary veins will be transplanted into the recipient Receives: Procedure: LA transplant |
What is being measured
The primary outcome is the main question the study is designed to answer.
Short term survival
Mortality rate at 30 days following transplantation.
Measured: 30 days
Secondary outcomes (4)
Pulmonary vein patency
The study team will assess for the flow through the transplanted pulmonary veins.
Measured: 30 days
Long term survival
Mortality rate at 6 months following transplantation.
Measured: 6 months
Long term pulmonary vein patency and gradient
The study team will assess for the flow through the transplanted pulmonary veins and any increased gradient through the transplanted pulmonary veins (gradient through transplanted veins that has been deemed greater than mild).
Measured: 6 months
Right ventricular pressure
The study team will assess for any increase in right ventricular pressure and/or concerns for developing pulmonary hypertension.
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Mar 2018
- Study startSep 2022 (estimated)
- Primary completionSep 2025 (estimated)
- Study completionSep 2025 (estimated)
Why it stopped: enrollment/ eligibility concerns
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for Pulmonary Vein StenosisStudies of the same condition, open and under way.
- More trials run by Boston Children's HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- Boston Children's Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, David Hoganson, Boston Children's Hospital
- Investigators
- David Hoganson, MD, Principal investigator, Boston Children's Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03456193
- Sponsor's protocol ID
- IRB-P00023581
- Status last verified
- Nov 2021
- First submitted
- 22 Feb 2018
- Last updated
- 28 May 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Devaney EJ, Chang AC, Ohye RG, Bove EL. Management of congenital and acquired pulmonary vein stenosis. Ann Thorac Surg. 2006 Mar;81(3):992-5; discussion 995-6. doi: 10.1016/j.athoracsur.2005.08.020.
PubMed 16488708Yun TJ, Coles JG, Konstantinov IE, Al-Radi OO, Wald RM, Guerra V, de Oliveira NC, Van Arsdell GS, Williams WG, Smallhorn J, Caldarone CA. Conventional and sutureless techniques for management of the pulmonary veins: Evolution of indications from postrepair pulmonary vein stenosis to primary pulmonary vein anomalies. J Thorac Cardiovasc Surg. 2005 Jan;129(1):167-74. doi: 10.1016/j.jtcvs.2004.08.043.
PubMed 15632839Bharat A, Epstein DJ, Grady M, Faro A, Michelson P, Sweet SC, Huddleston CB. Lung transplant is a viable treatment option for patients with congenital and acquired pulmonary vein stenosis. J Heart Lung Transplant. 2013 Jun;32(6):621-5. doi: 10.1016/j.healun.2013.03.002.
PubMed 23701851Sadr IM, Tan PE, Kieran MW, Jenkins KJ. Mechanism of pulmonary vein stenosis in infants with normally connected veins. Am J Cardiol. 2000 Sep 1;86(5):577-9, A10. doi: 10.1016/s0002-9149(00)01022-5.
PubMed 11009286
Study at a glance
From the registry record, last updated by the sponsor on 28 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Allogeneic Left Atrial and Pulmonary Vein Transplant for Pulmonary Vein Stenosis
- ClinicalTrials.gov ID
- NCT03456193
- Acronym / sponsor ID
- IRB-P00023581
- Conditions
- Pulmonary Vein Stenosis
- Study type
- Interventional
- Recruitment status
- WithdrawnReason stopped: enrollment/ eligibility concerns
- Enrolment
- 0 participants (actual)
- Lead sponsor
- Boston Children's HospitalUniversity, hospital or other
- Study start
- Sep 2022 (estimated)
- Primary completion
- Sep 2025 (estimated)
- Study completion
- Sep 2025 (estimated)
- First posted
- 7 Mar 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a prospective, single center, safety and feasibility trial to evaluate the transplantation of the left atrium and pulmonary veins in patients with pulmonary vein stenosis. Consented patients will be listed for transplantation. Once a suitable donor has been identified, the left atrium, pulmonary veins and complete lung block will be harvested from the donor and transported to Boston Children's Hospital as is the procedure for routine lung transplantation patients. The left atrium and pulmonary veins will be transplanted into the recipient. The recipient will receive the normal immunosuppression protocol used for heart transplantation.
This pilot study will include 5 patients.
Detailed description
Techniques for harvest of the posterior left atrium and pulmonary veins from a suitable organ donor have been well established as this is currently accomplished during every harvest of lungs for lung transplantation. The difference in this therapy is that the lung parenchyma will not be utilized. However, the harvest from the donor will be exactly the same with the full lung block typically harvested for lung transplant removed and transported back to the site of implantation. The exact extent of pulmonary vein utilization from the lung block will be determined at the time of implantation based on the exact anatomy and location of the pulmonary vein disease of the recipient.
As this represents a new transplantation approach, this program has been discussed with the United Network for Organ Sharing (UNOS) and the New England Organ Bank (NEOB). UNOS identified this as a new area of transplantation related to but separate from heart or lung transplantations. Eventually if this progresses to a national phase, it will require creation of a new patient waiting list and all the policies that accompany a new area of transplantation. Although there is enthusiasm at UNOS for this approach, they recommended that it be pursued as a regional research program as an initial step. The NEOB also has voiced support for this program in a meeting with them including their medical director. They are interested in supporting this program as a Region 1 research program and will perform a full evaluation for approval once local IRB approval has been granted. The Children's team will work closely with NEOB to create a list of potential patients and identify suitable donors.
Utilizing standardized harvesting techniques will minimize any changes to the current harvest approach and definition of tissue allocation during the harvest procedure. As the lung parenchyma is unnecessary, it is expected that suitable donors for left atrial transplant would come from two sources:
- The first source is brain dead donors in whom the lungs are not allocated for transplantation based on rejection of the lungs for quality or no matching donors.
- The second source is donors after cardiac death (DCD) which are utilized in the adult population for kidney, liver and lung transplantation. DCD organs are not currently utilized pediatric lung transplantation. However, as the viability of these tissues, including the entire lung block is well established, these represent a potential donor pool for left atrial transplant patients.
Certainly experience with preservation of the kidney grafts for hours or days with integrated perfusion systems has demonstrated the successful implantation of vascularized tissues appropriately preserved can be extended beyond the traditional four hour window targeted for lung transplantation. Kidney transplants are commonly done within 24 hours without evidence of impact on the vascular patency these grafts. In addition, only vascular tissue is being transplanted that has no effect on gas exchange or contractility. Accordingly it is expected that the goal implantation time for left atrial transplants after harvest will not need to be within the four to six hour window used for lung transplant but can be safely extended to 24 hours. This window extends the donor pool for left atrial transplants to the entire country.
Excision of recipient left atrium and stenotic pulmonary veins and implantation of left atrial graft The set up for the operation will be identical to all major cardiopulmonary bypass cardiac cases. The surgical approach for the recipient will likely be a clamshell incision that crosses the sternum in the fourth interspace. This is the same incision used for lung transplant. The patient will be cannulated for cardiopulmonary bypass in the distal aorta, SVC and low in the IVC. Cardiopulmonary bypass will be initiated and the patient will be cooled to 18°C. Prior to arresting the heart, the donor left atrium and pulmonary veins will be inspected in the lung block. The pulmonary veins from the donor will be mobilized and prepared for resection from the lung block.
The cross clamp will be applied and the heart arrested. The pulmonary veins of the recipient will be mobilized and transected beyond the level stenoses. The left atrium and pulmonary vein graft then be brought to the field and positioned in the orthotopic position.
The anastomosis of the pulmonary veins will be completed with a generous diameter of the anastomotic area to minimize any risk of late anastomotic narrowing even in the smallest of pulmonary vein segments. The donor left atrium will be anastomosed to the posterior left atrial cuff of the heart. Only the affected pulmonary veins with stenosis will be transplanted. This may be one or up to all 4 main pulmonary veins. If an individual pulmonary vein or side of pulmonary veins are unaffected, they will not have any manipulation or intervention on them. A formal atrial fenestration will be created. Post-bypass evaluation with transesophageal echocardiogram will assess pulmonary vein velocities and flow. The chest will be closed and patient transferred intubated to the ICU.
In the initial clinical experience with these transplants, a traditional immunosuppression protocol for heart transplants will be followed. Over time new protocols will be developed and tested which focused on minimizing the long-term immunosuppression regimens.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| LA transplantation | Experimental | Procedure: LA transplantThe left atrium and pulmonary veins will be transplanted into the recipient |
Who may qualify
- Ages
- Up to 17 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (2 listed)
- Pulmonary vein stenosis involving at least one but up to all of the main pulmonary veins following initial treatment, including but not limited to balloon dilation, stenting, surgical repair or chemotherapy
- Focal pulmonary stenosis limited to the main pulmonary veins or their first or second order branches.
Key exclusion criteria (18 listed)
- Diffuse pulmonary vein stenosis involving long segments of one or more pulmonary veins including diffuse stenosis into the second order pulmonary vein branches or beyond
- Significant underlying lung disease
- Irreversible pulmonary artery hypertension exceeding indexed 10 Woods units (WU)
- Irreversible multisystem organ failure; or additive effects of multiple systems affected making transplant survival unlikely
- Progressive systemic disease with early mortality (genetic/metabolic, idiopathic, syndromic)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| LA transplantThe proposed study treatment will include three central components: * Harvest of the left atrium and pulmonary veins from a suitable donor * Excision of the left atrium and portions of stenotic pulmonary veins from the patient with pulmonary vein stenosis * Implantation of the donor posterior left atrium and portions of pulmonary veins into the patient. | Procedure or surgery | LA transplantation |
Primary outcome
Short term survival
Time frame: 30 days
Mortality rate at 30 days following transplantation.
4 secondary outcomes
Pulmonary vein patency
Time frame: 30 days
Long term survival
Time frame: 6 months
Long term pulmonary vein patency and gradient
Time frame: 6 months
Right ventricular pressure
Time frame: 6 months
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 May 2026.
- Background: PubMed 16488708Devaney EJ, Chang AC, Ohye RG, Bove EL. Management of congenital and acquired pulmonary vein stenosis. Ann Thorac Surg. 2006 Mar;81(3):992-5; discussion 995-6. doi: 10.1016/j.athoracsur.2005.08.020.
- Background: PubMed 15632839Yun TJ, Coles JG, Konstantinov IE, Al-Radi OO, Wald RM, Guerra V, de Oliveira NC, Van Arsdell GS, Williams WG, Smallhorn J, Caldarone CA. Conventional and sutureless techniques for management of the pulmonary veins: Evolution of indications from postrepair pulmonary vein stenosis to primary pulmonary vein anomalies. J Thorac Cardiovasc Surg. 2005 Jan;129(1):167-74. doi: 10.1016/j.jtcvs.2004.08.043.
- Background: PubMed 23701851Bharat A, Epstein DJ, Grady M, Faro A, Michelson P, Sweet SC, Huddleston CB. Lung transplant is a viable treatment option for patients with congenital and acquired pulmonary vein stenosis. J Heart Lung Transplant. 2013 Jun;32(6):621-5. doi: 10.1016/j.healun.2013.03.002.
- Background: PubMed 11009286Sadr IM, Tan PE, Kieran MW, Jenkins KJ. Mechanism of pulmonary vein stenosis in infants with normally connected veins. Am J Cardiol. 2000 Sep 1;86(5):577-9, A10. doi: 10.1016/s0002-9149(00)01022-5.
Related trials for Pulmonary Vein Stenosis
RecruitingPhase 1
Calculating Wall Shear Stress in Infant Pulmonary Veins
Pulmonary Vein Stenosis
Active, not recruiting
Predicting Pediatric Pulmonary Vein Stenosis Outcomes Using Data Acquired During a Cardiac Catheterization
Pulmonary Vein Stenosis
RecruitingObservational study
Genesis Electrical Impedance Tomography (EIT): A Preliminary Study
Premature Infant, Chronic Respiratory Disease
RecruitingObservational study
An Integrated Prenatal and Postnatal Treatment Model for the Treatment of Newborns With Critical Congenital Heart Disease
Congenital Heart Disease, Coarctation of Aorta
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
David Hoganson, MD principal investigator
Boston Children's Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing LA transplant in people with Pulmonary Vein Stenosis, run by Boston Children's Hospital at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 18 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 28 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Short term survival (time frame: 30 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03456193, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 May 2026.